Home LiteratureArticle Details
PMID: 16103173 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope.

Journal of virology ·Vol. 79 ·No. 17 ·2005-09-00 ·Pages 11214-24

Doria-Rose NA, Learn GH, Rodrigo AG, Nickle DC, Li F, Mahalanabis M, Hensel MT, McLaughlin S, Edmonson PF, Montefiori D, Barnett SW, Haigwood NL, Mullins JI

Abstract

Human immunodeficiency virus type 1 (HIV-1) is a difficult target for vaccine development, in part because of its ever-expanding genetic diversity and attendant capacity to escape immunologic recognition. Vaccine efficacy might be improved by maximizing immunogen antigenic similarity to viruses likely to be encountered by vaccinees. To this end, we designed a prototype HIV-1 envelope vaccine using a deduced ancestral state for the env gene. The ancestral state reconstruction method was shown to be >95% accurate by computer simulation and 99.8% accurate when estimating the known inoculum used in an experimental infection study in rhesus macaques. Furthermore, the deduced ancestor gene differed from the set of sequences used to derive the ancestor by an average of 12.3%, while these latter sequences were an average of 17.3% different from each other. A full-length ancestral subtype B HIV-1 env gene was constructed and shown to produce a glycoprotein of 160 kDa that bound and fused with cells expressing the HIV-1 coreceptor CCR5. This Env was also functional in a virus pseudotype assay. When either gp160- or gp140-expressing plasmids and recombinant gp120 were used to immunize rabbits in a DNA prime-protein boost regimen, the artificial gene induced immunoglobulin G antibodies capable of weakly neutralizing heterologous primary HIV-1 strains. The results were similar for rabbits immunized in parallel with a natural isolate, HIV-1 SF162. Further design efforts to better present conserved neutralization determinants are warranted.

MeSH Terms
AIDS Vaccines/immunology Amino Acid Sequence Animals Gene Products, env/chemistry,genetics,immunology HIV Antibodies/immunology HIV Envelope Protein gp120/genetics,immunology HIV Envelope Protein gp160/genetics,immunology,metabolism HIV-1/immunology Immunization Immunization, Secondary Molecular Sequence Data Neutralization Tests Phylogeny Rabbits Receptors, CCR5/metabolism Recombinant Proteins/immunology Solubility Vaccines, Synthetic/immunology Viral Envelope Proteins/genetics,immunology env Gene Products, Human Immunodeficiency Virus
Chemicals
AIDS Vaccines Gene Products, env HIV Antibodies HIV Envelope Protein gp120 HIV Envelope Protein gp160 Receptors, CCR5 Recombinant Proteins Vaccines, Synthetic Viral Envelope Proteins env Gene Products, Human Immunodeficiency Virus gp140 envelope protein, Human immunodeficiency virus 1
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Doria-Rose N A
Seattle Biomedical Research Institute, Washington, USA.
Learn G H
Rodrigo A G
Nickle D C
Li F
Mahalanabis M
Hensel M T
McLaughlin S
Edmonson P F
Montefiori D
Barnett S W
Haigwood N L
Mullins J I
References (62)
62 references, click to expand
  1. HIV sequence databases.
    AIDS Rev. 2003 Jan-Mar;5(1):52-61 PMID: 12875108
  2. HIV-1 prophylactic vaccine trials in Thailand.
    Curr HIV Res. 2005 Jan;3(1):17-30 PMID: 15638720
  3. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.
    J Virol. 2003 Nov;77(21):11563-77 PMID: 14557642
  4. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.
    J Virol. 2003 Dec;77(24):13376-88 PMID: 14645592
  5. HIV vaccine development: lessons from the past and promise for the future.
    Curr HIV Res. 2003 Jan;1(1):101-20 PMID: 15043215
  6. Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.
    J Virol. 2004 May;78(10):5270-8 PMID: 15113908
  7. Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses.
    Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S53-64 PMID: 15285705
  8. Immunogen sequence: the fourth tier of AIDS vaccine design.
    Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S151-9 PMID: 15285713
  9. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity.
    Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S161-8 PMID: 15285714
  10. Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses.
    Nature. 1987 Apr 9-15;326(6113):610-3 PMID: 3104797
  11. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes.
    J Immunol. 1991 Nov 1;147(9):3128-32 PMID: 1717587
  12. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.
    Science. 1991 Oct 4;254(5028):105-8 PMID: 1718036
  13. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.
    J Virol. 1992 Jan;66(1):172-82 PMID: 1727480
  14. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.
    J Virol. 1992 Apr;66(4):2232-9 PMID: 1548759
  15. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.
    Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11478-82 PMID: 8265577
  16. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
    Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 PMID: 7984417
  17. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.
    N Engl J Med. 1995 Jan 26;332(4):201-8 PMID: 7808485
  18. The genetic data environment an expandable GUI for multiple sequence analysis.
    Comput Appl Biosci. 1994 Dec;10(6):671-5 PMID: 7704666
  19. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.
    J Virol. 1995 Nov;69(11):6705-11 PMID: 7474080
  20. Maintaining the integrity of human immunodeficiency virus sequence databases.
    J Virol. 1996 Aug;70(8):5720-30 PMID: 8764096
  21. An improved plasmid DNA expression vector for direct injection into skeletal muscle.
    Hum Gene Ther. 1996 Jun 20;7(10):1205-17 PMID: 8793545
  22. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.
    J Virol. 1999 Dec;73(12):10489-502 PMID: 10559367
  23. Codon usage tabulated from international DNA sequence databases: status for the year 2000.
    Nucleic Acids Res. 2000 Jan 1;28(1):292 PMID: 10592250
  24. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys.
    Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4192-7 PMID: 10759543
  25. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    J Virol. 2000 Sep;74(18):8358-67 PMID: 10954535
  26. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
    J Virol. 2001 Jan;75(2):645-53 PMID: 11134278
  27. Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing.
    Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4587-92 PMID: 11287644
  28. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    J Virol. 2001 Jun;75(12):5526-40 PMID: 11356960
  29. Evolutionary and immunological implications of contemporary HIV-1 variation.
    Br Med Bull. 2001;58:19-42 PMID: 11714622
  30. Clinical trials of HIV vaccines.
    Annu Rev Med. 2002;53:207-21 PMID: 11818471
  31. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.
    J Virol. 2002 Mar;76(6):2835-47 PMID: 11861851
  32. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.
    J Virol. 2002 May;76(9):4199-211 PMID: 11932385
  33. Past, present and future of HIV vaccine trials in developing countries.
    Vaccine. 2002 May 6;20(15):1897-8 PMID: 11983240
  34. HIV vaccine strategies.
    Vaccine. 2002 May 6;20(15):1945-7 PMID: 11983251
  35. Association of chemokine-mediated block to HIV entry with coreceptor internalization.
    J Biol Chem. 2002 May 10;277(19):17291-9 PMID: 11782464
  36. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus.
    AIDS Res Hum Retroviruses. 2002 May 20;18(8):567-76 PMID: 12036486
  37. Diversity considerations in HIV-1 vaccine selection.
    Science. 2002 Jun 28;296(5577):2354-60 PMID: 12089434
  38. HIV-1 diversity and vaccine development.
    Science. 2002 Jun 28;296(5577):2335 PMID: 12090274
  39. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.
    Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11842-7 PMID: 12192089
  40. Consensus and ancestral state HIV vaccines.
    Science. 2003 Mar 7;299(5612):1515-8; author reply 1515-8 PMID: 12624248
  41. Antibody neutralization and escape by HIV-1.
    Nature. 2003 Mar 20;422(6929):307-12 PMID: 12646921
  42. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
    J Virol. 2003 May;77(10):5889-901 PMID: 12719582
  43. Predicting demographic group structures based on DNA sequence data.
    Mol Biol Evol. 2003 Jul;20(7):1168-80 PMID: 12777527
  44. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.
    J Infect Dis. 2003 Jul 15;188(2):219-27 PMID: 12854076
  45. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    J Virol. 1997 May;71(5):3734-41 PMID: 9094648
  46. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection.
    J Virol. 1997 May;71(5):3932-9 PMID: 9094670
  47. Seq-Gen: an application for the Monte Carlo simulation of DNA sequence evolution along phylogenetic trees.
    Comput Appl Biosci. 1997 Jun;13(3):235-8 PMID: 9183526
  48. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.
    J Immunol. 1997 Jul 1;159(1):279-89 PMID: 9200464
  49. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.
    Vaccine. 1997 Jun;15(8):869-73 PMID: 9234536
  50. Evolution of a simian immunodeficiency virus pathogen.
    J Virol. 1998 Jan;72(1):405-14 PMID: 9420239
  51. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
    AIDS Res Hum Retroviruses. 1998 Jan 20;14(2):151-5 PMID: 9462925
  52. A role for carbohydrates in immune evasion in AIDS.
    Nat Med. 1998 Jun;4(6):679-84 PMID: 9623976
  53. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  54. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.
    J Virol. 1998 Sep;72(9):6988-96 PMID: 9696790
  55. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
    AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S325-31 PMID: 9814961
  56. MODELTEST: testing the model of DNA substitution.
    Bioinformatics. 1998;14(9):817-8 PMID: 9918953
  57. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.
    Glycobiology. 2004 Dec;14(12):1229-46 PMID: 15175256
  58. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.
    J Infect Dis. 2004 Dec 1;190(11):1962-9 PMID: 15529261
  59. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    J Virol. 2004 Dec;78(23):13232-52 PMID: 15542675
  60. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
    Virology. 2005 Jan 5;331(1):33-46 PMID: 15582651
  61. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.
    J Virol. 2005 Jan;79(2):1154-63 PMID: 15613343
  62. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
    J Virol. 2003 Sep;77(18):9993-10003 PMID: 12941910
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2005-09-00
Pages
11214-24
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC1193599
Subset
IM
Grants
PHS HHS · T32A107509 · United States
NCI NIH HHS · T32CA0922925 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com